Clinical Nurse Specialist in Falls Church, VA Accepting Medicare

4 Clinical Nurse Specialist nurses found. Showing 1 - 4

Hartley Wenger, Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 3300 Gallows Rd, Falls Church, VA 22042 Phone: 703-776-7805

Ms. Sharon Ellen Hall, CNS-BC Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Not Enrolled in Medicare Practice Location: 7700 Leesburg Pike, #200, Falls Church, VA 22043 Phone: 703-437-7285    Fax: 703-437-8410

Dr. Salome Maria Loera, DNP, CNS Clinical Nurse Specialist - Acute Care Medicare: Not Enrolled in Medicare Practice Location: 3300 Gallows Rd # 7.107, Falls Church, VA 22042 Phone: 425-614-8735

Linda D Grey, RN MSN CS Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Not Enrolled in Medicare Practice Location: 131 Great Falls St, Suite 101, Falls Church, VA 22046 Phone: 703-533-1359    Fax: 703-533-8772

News Archive

arGEN-X introduces NHance technology to create therapeutic antibodies

arGEN-X announces today the launch of NHance, its latest cutting-edge technology enabling the creation of truly differentiated human antibody therapeutics.

Tarceva should be tested as front-line therapy for older lung cancer patients

The tyrosine kinase inhibitor erlotinib (Tarceva) showed encouraging activity with relatively tolerable side effects in elderly, previously untreated patients with advanced non-small cell lung cancer (NSCLC), reports a team led by investigators from Dana-Farber Cancer Institute in Boston.

Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myeloma

Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein (KSP) inhibitor, ARRY-520. The data, which were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma.

Thrombogenics issues business update and half year results

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

Read more Medical News

› Verified 1 days ago